placeholder image
S. Dasen All authors
About
Publications While At 开云体育
selected publications
Abstract
  • Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with Pembrolizumab: clinical update [abstract]. 
    Journal of Clinical Oncology. 2024
    • Contact
    full name
  • S. Dasen
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration